Last updated on November 2019

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant


Brief description of study

This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebocontrolled study for prevention of acute GVHD (aGVHD) in subjects undergoing an allogeneic hematopoietic cell transplant (HCT).

Clinical Study Identifier: NCT03805789

Find a site near you

Start Over